



(51) International Patent Classification:

C07D 417/12 (2006.01) *A61K 31/427* (2006.01)
C07D 417/14 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:

PCT/US2012/067132

(22) International Filing Date:

29 November 2012 (29.11.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/564,773 29 November 2011 (29.11.2011) US

(71) Applicant: TAIVEX THERAPEUTICS CORPORATION [CN/CN]; 17th Floor, 3 YuanQu Street, Nangang District, Taipei City, 115 (TW).

(72) Inventors; and

(71) Applicants (for US only): HUANG, Yu-Ling [CN/CN]; 62-7F, West Yuan, National Tsing Hua University, Hsin-chu City, 300 (TW). CHUANG, Shih-Hsien [CN/CN]; No.34, Guosing St, Taoyuan County, Taoyuan City, 330 (TW). LEE, Ying-Shuan Eda [CN/CN]; 137 Renai Rd. Sec. 4, 11F-2, Daan District, Taipei, 10689 (TW). HUANG, Jiann-Jyh [CN/CN]; No.44, Wenhua St., Luodong Township, Yilan County, 264 (TW). LAU, John-

son [US/US]; 9 Seabluff, Newport Beach, California 92660 (US).

(74) Agents: FESSENMAIER, Martin et al.; Fish & Associates, PC, 2603 Main Street, Suite 1000, Irvine, California 92614 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: IMPROVED MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR




FIG. 1

(57) Abstract: Compounds, compositions, and methods for modulation of Hec1/Nek2 interaction are provided. Such compounds disrupt Nek2/Hec1 binding and may be useful as chemotherapeutic agents for neoplastic diseases.



Published:

— *with international search report (Art. 21(3))*

— *with amended claims (Art. 19(1))*